triple-negative breast cancer

Why Switching Antibody‑Drug Conjugates (ADCs) Could Extend Breast Cancer Survival

Recent pre‑clinical research from the University of Hawaiʻi Cancer Center reveals a simple yet powerful strategy: after a tumor stops responding to one ADC, clinicians should select a follow‑up ADC that carries a different cytotoxic payload. In laboratory and animal models of both HER2‑positive and triple‑negative breast cancer, this “payload swap” restored tumor control and prolonged treatment benefit.

How ADCs Work – A Quick Primer

ADCs are “smart bombs” that pair a monoclonal antibody with a potent chemotherapy agent. The antibody homes in on a specific cancer‑cell marker (such as HER2 or EGFR), delivering the drug directly to the tumor while sparing healthy tissue. Learn more about ADC mechanics.

The Cross‑Resistance Problem

Many FDA‑approved breast‑cancer ADCs use DNA‑targeting drugs (e.g., payloads that damage the tumor’s genetic material). When a tumor becomes resistant to one DNA‑targeting ADC, switching to another ADC with the same payload often yields only marginal gains because the cancer cells have already activated repair pathways that neutralize the drug.

Payload Switching: What the Study Shows

• Model systems: HER2‑positive and triple‑negative breast‑cancer xenografts.
• First ADC: DNA‑damage payload (e.g., maytansine‑derivative).
• Second ADC: Microtubule‑disrupting payload (e.g., auristatin‑derivative).
• Result: Tumors that had progressed on the first ADC regained sensitivity to the second, leading to prolonged tumor regression.

These findings suggest that “cross‑resistance” is largely payload‑specific rather than antibody‑specific, opening a new avenue for precision sequencing of ADC therapies.

Real‑World Example: The T‑DX (Trastuzumab‑Deruxtecan) Journey

In the pivotal DESTINY‑Breast trials, patients with HER2‑positive disease who progressed on T‑DX were later treated with an ADC bearing a tubulin‑binding payload (e.g., sacituzumab govitecan). Early data, published in Nature, observed a 30% objective response rate, supporting the payload‑switch concept.

Future Trends Shaping ADC Therapy

1. Adaptive “Payload‑Matching” Clinical Trials

Investigators are designing trials that test the tumor’s resistance mechanisms (e.g., DNA‑repair up‑regulation) before assigning the next ADC. This biomarker‑driven approach aligns with the broader move toward precision oncology.

2. Multi‑Payload ADC Platforms

Next‑generation ADCs can carry two distinct drugs within a single conjugate, offering simultaneous attack on DNA and microtubules. Early-phase studies from NEJM report promising activity in resistant breast‑cancer models.

3. Real‑Time Monitoring with Liquid Biopsies

Circulating tumor DNA (ctDNA) assays can detect emerging resistance signatures while a patient is still on therapy, allowing clinicians to pre‑emptively switch payloads before clinical progression.

Practical Guidance for Oncologists

• Assess the resistance pathway: Use genomic profiling or ctDNA to identify whether DNA repair, drug efflux, or tubulin alterations dominate.
• Choose a payload with a different mechanism of action: Switch from DNA‑damaging to microtubule‑disrupting agents, or vice versa.
• Maintain the same antibody when possible: The targeting component can stay unchanged, preserving tumor specificity.
• Consider clinical trial enrollment: Many centers now offer adaptive ADC sequencing protocols.

Frequently Asked Questions

What is an ADC?

An antibody‑drug conjugate (ADC) combines a monoclonal antibody with a potent chemotherapy drug, delivering the payload directly to cancer cells.

Why does changing the drug payload help?

Resistance often develops against the specific cytotoxic mechanism (e.g., DNA damage). Switching to a drug that works via a different pathway (e.g., microtubule inhibition) bypasses that resistance.

Are there FDA‑approved ADCs with different payloads?

Yes. Trastuzumab‑deruxtecan (DNA‑damage) and sacituzumab‑govitecan (microtubule‑disruption) are both approved for breast cancer, providing clinicians with distinct options.

Can the antibody stay the same when I switch ADCs?

In many cases, yes. The study shows that even with the same target antigen, changing the payload restores efficacy.

How soon will this strategy be available in routine practice?

Adaptive trials are already enrolling patients, and results are expected within the next few years. Early adoption in academic centers is likely.

Pro Tip: Building an ADC Sequencing Plan

Start with a baseline genomic panel at diagnosis. If progression occurs, re‑biopsy or run a liquid biopsy to pinpoint the resistance mechanism. Then, select a second ADC with a payload that targets a complementary pathway. Document the sequence in the patient’s chart for future reference.

What’s Next?

As more data emerge, the oncology community anticipates a paradigm shift—from “one‑size‑fits‑all” ADC prescribing to a dynamic, payload‑tailored regimen that maximizes durable responses.

Have thoughts on ADC sequencing or experiences with breast‑cancer treatments? Leave a comment below and join the conversation!